Gemcitabine (Synonyms: 吉西他滨; LY 188011)

目录号: HY-17026 纯度: 99.96%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Gemcitabine (LY 188011) 是一种嘧啶核苷类似物抗代谢药 (nucleoside antimetabolite/analog) 和抗肿瘤剂。Gemcitabine 抑制 DNA 合成 (DNA synthesis) 和修复，导致细胞自噬 (autophagy) 和凋亡 (apoptosis)。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Gemcitabine Chemical Structure

CAS No. : 95058-81-4

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥792	In-stock
100 mg	￥720	In-stock
200 mg	￥1080	In-stock
500 mg	￥1980	In-stock
1 g	￥3100	In-stock
5 g	￥5900	In-stock
10 g		询价
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Gemcitabine:

MCE 顾客使用本产品发表的 151 篇科研文献

Proliferation Assay

: Gemcitabine purchased from MCE. Usage Cited in: Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392(5):615-622. [Abstract]; The expression level of p-JAK2, p-STAT3, Bcl-XL, and Mcl-1 in PANC-1 cells is detected by western blot analysis and is all down-regulated in the treatment groups.

: Gemcitabine purchased from MCE. Usage Cited in: Chem Biol Interact. 2018 Jun 25;290:44-51. [Abstract]; U2OS and MG-63 cells are treated with Gemcitabine, Licoricidin, or Gemcitabine+Licoricidin for 24 h, followed by the determination of active caspse-3 protein level using western blot. Cells without treatment are used as Control.

: Gemcitabine purchased from MCE. Usage Cited in: J Biol Chem. 2017 Jun 2;292(22):9136-9149. [Abstract]; The plate clone formation of SW480 and SW620 cells with Gemcitabine (8 nM in SW480 and 16 nM in SW620) and/or PX-12 (4 μM in SW480 and 8 μM in SW620).

Gemcitabine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis^[1]^[2].

IC₅₀ & Target

DNA synthesis^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
8305C	IC₅₀	4.53 μM Compound: Gemcitabine	Cytotoxicity against human 8305C cells after 24 hrs by MTT assay Cytotoxicity against human 8305C cells after 24 hrs by MTT assay	[PMID: 24436994]
A2780	IC₅₀	0.0166 μM Compound: Gemcitabine	Antiproliferative activity against human A2780 cells expressing p53 gene after 72 hrs by proliferative assay Antiproliferative activity against human A2780 cells expressing p53 gene after 72 hrs by proliferative assay	[PMID: 18469809]
A2780	IC₅₀	0.035 μM Compound: Gemcitabine	Antiproliferative activity against human A2780 cells expressing p53 after 72 hrs by celltiter-glo assay Antiproliferative activity against human A2780 cells expressing p53 after 72 hrs by celltiter-glo assay	[PMID: 20873740]
A2780	IC₅₀	0.31 μM Compound: Gemcitabine	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 19362474]
A2780	IC₅₀	1.5 nM Compound: dFdc	Growth inhibition of A2780 cells by SRB assay Growth inhibition of A2780 cells by SRB assay	[PMID: 17602464]
A2780	IC₅₀	15 nM Compound: dFdc	Growth inhibition of A2780 cells by SRB assay in presence of dipyridamole Growth inhibition of A2780 cells by SRB assay in presence of dipyridamole	[PMID: 17602464]
A549	IC₅₀	< 0.0039 μM Compound: 1, gemcitabine, GEM, dFdC	Cytotoxicity against human A549 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid Cytotoxicity against human A549 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid	[PMID: 25874330]
A549	IC₅₀	> 1 μM Compound: 1, gemcitabine, GEM, dFdC	Cytotoxicity against human A549 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid Cytotoxicity against human A549 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid	[PMID: 25874330]
A549	EC₅₀	> 100 μM Compound: 11	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
A549	IC₅₀	0.0039 μM Compound: 1, gemcitabine, GEM, dFdC	Cytotoxicity against human A549 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid Cytotoxicity against human A549 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid	[PMID: 25874330]
A549	IC₅₀	0.0068 μM Compound: 1, gemcitabine, GEM, dFdC	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 25874330]
A549	IC₅₀	0.02 μM Compound: gemcitabine	Antiproliferative activity at human A549 cells after 72 hrs by MTT assay Antiproliferative activity at human A549 cells after 72 hrs by MTT assay	[PMID: 22861499]
A549	IC₅₀	0.029 μM Compound: 1, gemcitabine, GEM, dFdC	Cytotoxicity against human A549 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid Cytotoxicity against human A549 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid	[PMID: 25874330]
A549	IC₅₀	0.044 μM Compound: Gemcitabine	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 34619466]
A549	IC₅₀	0.05 μM Compound: Gemcitabine	Antiproliferative activity against human A549 cells after 3 days by MTS assay Antiproliferative activity against human A549 cells after 3 days by MTS assay	[PMID: 30281308]
A549	IC₅₀	0.05 μM Compound: Gemcitabine	Cytostatic activity against human A549 cells after 3 days by MTS assay Cytostatic activity against human A549 cells after 3 days by MTS assay	[PMID: 30108897]
A549	IC₅₀	0.05 μM Compound: Gemcitabine	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 28221790]
A549	IC₅₀	0.09 μM Compound: gemcitabine	Cytotoxicity against human A549 cells by sulforhodamine B method Cytotoxicity against human A549 cells by sulforhodamine B method	[PMID: 19691349]
A549	IC₅₀	0.26 μM Compound: Gemcitabine	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 27670098]
A549	IC₅₀	1.4 μM Compound: Gemcitabine	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19362474]
A549	IC₅₀	13.1 μM Compound: gemicitabine	Cytotoxicity against A549 cells after 72 hrs by SRB assay Cytotoxicity against A549 cells after 72 hrs by SRB assay	[PMID: 17419604]
A549	IC₅₀	14 nM Compound: dFdc	Growth inhibition of A549 cells by SRB assay Growth inhibition of A549 cells by SRB assay	[PMID: 17602464]
A549	IC₅₀	18.8 nM Compound: GEM	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34967607]
A549	IC₅₀	2.69 μM Compound: 7	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C5MD00158G
A549	IC₅₀	225 nM Compound: dFdc	Growth inhibition of A549 cells by SRB assay in presence of dipyridamole Growth inhibition of A549 cells by SRB assay in presence of dipyridamole	[PMID: 17602464]
A549	IC₅₀	5.05 μM Compound: 1; dFdC	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
ACHN	IC₅₀	0.48 μM Compound: Gemcitabine	Cytotoxicity against human ACHN cells after 48 hrs by WST-8 assay Cytotoxicity against human ACHN cells after 48 hrs by WST-8 assay	[PMID: 22342146]
ASPC1	IC₅₀	26.8 μM Compound: GCT	Antiproliferative activity against human AsPC1 cells after 72 hrs by CCK8 assay Antiproliferative activity against human AsPC1 cells after 72 hrs by CCK8 assay	[PMID: 28576633]
ASPC1	IC₅₀	29.1 μM Compound: Gemcitabine	Cytotoxicity against human ASPC1 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay Cytotoxicity against human ASPC1 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay	[PMID: 34342431]
ASPC1	IC₅₀	35.11 μM Compound: Gemcitabine	Anticancer activity against human ASPC1 cells assessed as cell growth inhibition measured after 72 hrs by Cell-Titre Glo luminescent cell viability assay Anticancer activity against human ASPC1 cells assessed as cell growth inhibition measured after 72 hrs by Cell-Titre Glo luminescent cell viability assay	[PMID: 34838335]
ASPC1	IC₅₀	4 nM Compound: GEM	Cytotoxicity against human Aspc-1 cells by crystal violet staining Cytotoxicity against human Aspc-1 cells by crystal violet staining	[PMID: 20930123]
ASPC1	IC₅₀	7.5 μM Compound: GEM	Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35380848]
B16-F10	IC₅₀	0.26 μM Compound: GEM	Cytotoxicity against mouse B16F10 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against mouse B16F10 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108970]
BEAS-2B	IC₅₀	0.037 μM Compound: Gemcitabine	Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 34619466]
Bel-7402	IC₅₀	0.84 μM Compound: Gemcitabine	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 19362474]
BJ	IC₅₀	> 50 μM Compound: Gemcitabine	Antiproliferative activity against human BJ cells after 3 days by MTS assay Antiproliferative activity against human BJ cells after 3 days by MTS assay	[PMID: 30281308]
BJ	IC₅₀	> 50 μM Compound: Gemcitabine	Cytostatic activity against human BJ cells after 3 days by MTS assay Cytostatic activity against human BJ cells after 3 days by MTS assay	[PMID: 30108897]
BJ	IC₅₀	> 50 μM Compound: Gemcitabine	Cytotoxicity against human BJ cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against human BJ cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 28221790]
BJ	IC₅₀	9.88 μM Compound: Gemcitabine	Cytotoxicity against human BJ cells after 3 days by MTT assay Cytotoxicity against human BJ cells after 3 days by MTT assay	[PMID: 21711054]
BT-549	GI₅₀	0.004 μM Compound: gemcitabine	Cytotoxicity against human BT549 cells after 5 days by SRB assay Cytotoxicity against human BT549 cells after 5 days by SRB assay	[PMID: 19929004]
BT-549	IC₅₀	0.008 μM Compound: Gemcitabine	Cytotoxicity against human BT549 cells after 3 days by MTT assay Cytotoxicity against human BT549 cells after 3 days by MTT assay	[PMID: 21711054]
BV-173	IC₅₀	0.001 μM Compound: Gemcitabine	Cytotoxicity against human BV173 cells after 3 days by MTT assay Cytotoxicity against human BV173 cells after 3 days by MTT assay	[PMID: 21711054]
BXPC-3	IC₅₀	0.005 μM Compound: 19	Antiproliferative activity against human BXPC-3 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay Antiproliferative activity against human BXPC-3 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay	[PMID: 32858470]
BXPC-3	IC₅₀	0.04 μM Compound: GEM	Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35380848]
BXPC-3	IC₅₀	0.05 μM Compound: Gemcitabine	Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35439009]
BXPC-3	IC₅₀	0.67 μM Compound: 1, dFdC, GEM, Gemcitabine	Cytostatic activity against human BxPC3 cells after 72 hrs by MTS assay Cytostatic activity against human BxPC3 cells after 72 hrs by MTS assay	[PMID: 24471998]
BXPC-3	EC₅₀	10 nM Compound: 1	Cytotoxicity against human BxPC3 cells after 5 days by PrestoBlue assay Cytotoxicity against human BxPC3 cells after 5 days by PrestoBlue assay	[PMID: 24867590]
BXPC-3	IC₅₀	130 nM Compound: 1; dFdC	Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay	[PMID: 33479633]
BXPC-3	IC₅₀	2.9 μM Compound: Gemcitabine	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 19362474]
BXPC-3	IC₅₀	20.2 μM Compound: GCT	Antiproliferative activity against human BxPC3 cells after 72 hrs by CCK8 assay Antiproliferative activity against human BxPC3 cells after 72 hrs by CCK8 assay	[PMID: 28576633]
BXPC-3	IC₅₀	25.9 μM Compound: Gemcitabine	Cytotoxicity against human BXPC-3 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay Cytotoxicity against human BXPC-3 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay	[PMID: 34342431]
BXPC-3	GI₅₀	3.64 nM Compound: Gem	Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay	[PMID: 23094992]
BXPC-3	GI₅₀	3.64 μM Compound: Gem	Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay	[PMID: 22512908]
BXPC-3	IC₅₀	5.71 μM Compound: Gemcitabine	Antiproliferative activity against human BxPC3 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human BxPC3 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay	[PMID: 31191868]
BXPC-3	IC₅₀	6 nM Compound: Gemcitabine	Growth inhibition of human BxPC3 cells after 96 hrs by SRB assay Growth inhibition of human BxPC3 cells after 96 hrs by SRB assay	[PMID: 29356532]
C2D cell line	IC₅₀	0.0037 μM Compound: Gemcitabine	Cytotoxicity against mouse C2D cell line assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against mouse C2D cell line assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 27010926]
C2G cell line	IC₅₀	0.0037 μM Compound: Gemcitabine	Cytotoxicity against mouse C2G cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against mouse C2G cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 27010926]
C6	IC₅₀	0.504 μM Compound: Gemcitabine	Cytotoxicity against rat C6 cells after 3 days by MTT assay Cytotoxicity against rat C6 cells after 3 days by MTT assay	[PMID: 21711054]
Caco-2	IC₅₀	> 100 μM Compound: 1; dFdC	Antiproliferative activity against human Caco2 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human Caco2 cells after 48 hrs by sulforhodamine B assay	[PMID: 28495087]
Caco-2	GI₅₀	0.18 μM Compound: gemcitabine	Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay	[PMID: 18588281]
Caco-2	IC₅₀	9.4 μM Compound: Gemcitabine	Antiproliferative activity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33964437]
Calu-1	IC₅₀	0.52 μM Compound: Gemcitabine	Cytotoxicity against human Calu1 cells after 48 hrs by WST-8 assay Cytotoxicity against human Calu1 cells after 48 hrs by WST-8 assay	[PMID: 22342146]
CAPAN-1	IC₅₀	0.02 μM Compound: Gemcitabine	Antiproliferative activity against human Capan-1 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human Capan-1 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32007666]
CAPAN-1	IC₅₀	19 nM Compound: Gemcitabine	Growth inhibition of human Capan1 cells after 96 hrs by SRB assay Growth inhibition of human Capan1 cells after 96 hrs by SRB assay	[PMID: 29356532]
Capan-2	IC₅₀	1.7 μM Compound: Gemcitabine	Cytotoxicity against human Capan2 cells after 72 hrs by MTT assay Cytotoxicity against human Capan2 cells after 72 hrs by MTT assay	[PMID: 19362474]
Capan-2	IC₅₀	40.791 μM Compound: Gemcitabine	Cytotoxicity against human Capan2 cells incubated for 24 hrs by MTT assay Cytotoxicity against human Capan2 cells incubated for 24 hrs by MTT assay	[PMID: 30904782]
CCRF-CEM	IC₅₀	0.02 μM Compound: Gemcitabine	Antiproliferative activity against human CCRF-CEM cells after 3 days by MTS assay Antiproliferative activity against human CCRF-CEM cells after 3 days by MTS assay	[PMID: 30281308]
CCRF-CEM	IC₅₀	0.02 μM Compound: Gemcitabine	Cytostatic activity against human CCRF-CEM cells after 3 days by MTS assay Cytostatic activity against human CCRF-CEM cells after 3 days by MTS assay	[PMID: 30108897]
CCRF-CEM	IC₅₀	0.02 μM Compound: Gemcitabine	Cytotoxicity against daunorubicin resistant human CCRF-CEM cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against daunorubicin resistant human CCRF-CEM cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 28221790]
CCRF-CEM	IC₅₀	0.069 μM Compound: 2a, dFdC, Gemcitabine	Cytostatic activity against human CEM cells after 3 days by coulter counter analysis Cytostatic activity against human CEM cells after 3 days by coulter counter analysis	[PMID: 24341356]
CCRF-CEM	IC₅₀	0.086 μM Compound: 1, dFdC, GEM, Gemcitabine	Cytostatic activity against human CEM cells after 72 hrs by coulter counter analysis Cytostatic activity against human CEM cells after 72 hrs by coulter counter analysis	[PMID: 24471998]
CCRF-CEM	IC₅₀	1000 nM Compound: dFdc	Growth inhibition of CEM cells by SRB assay in presence of dipyridamole Growth inhibition of CEM cells by SRB assay in presence of dipyridamole	[PMID: 17602464]
CCRF-CEM	IC₅₀	100000 nM Compound: dFdc	Growth inhibition of dCK deficient CEM cells by SRB assay in presence of dipyridamole Growth inhibition of dCK deficient CEM cells by SRB assay in presence of dipyridamole	[PMID: 17602464]
CCRF-CEM	IC₅₀	130 nM Compound: dFdc	Growth inhibition of CEM cells by SRB assay Growth inhibition of CEM cells by SRB assay	[PMID: 17602464]
CCRF-CEM	IC₅₀	50000 nM Compound: dFdc	Growth inhibition of dCK deficient CEM cells by SRB assay Growth inhibition of dCK deficient CEM cells by SRB assay	[PMID: 17602464]
CCRF-CEM	IC₅₀	7.6 μM Compound: 2a, dFdC, Gemcitabine	Cytostatic activity against human dCK-deficient CEM cells after 3 days by coulter counter analysis Cytostatic activity against human dCK-deficient CEM cells after 3 days by coulter counter analysis	[PMID: 24341356]
CEM-DNR	IC₅₀	0.1 μM Compound: Gemcitabine	Cytostatic activity against human CEM/DNR cells after 3 days by MTS assay Cytostatic activity against human CEM/DNR cells after 3 days by MTS assay	[PMID: 30108897]
CFPAC-1	IC₅₀	0.022 μM Compound: Gemcitabine	Cytotoxicity against human CFPAC-1 cells incubated for 24 hrs by MTT assay Cytotoxicity against human CFPAC-1 cells incubated for 24 hrs by MTT assay	[PMID: 30904782]
CFPAC-1	IC₅₀	0.35 μM Compound: Gemcitabine, dFdC	Cytotoxicity against human CFPAC-1 cells assessed as reduction of cell survival after 96 hrs by MTT assay Cytotoxicity against human CFPAC-1 cells assessed as reduction of cell survival after 96 hrs by MTT assay	[PMID: 24631359]
CFPAC-1	IC₅₀	0.47 μM Compound: Gemcitabine, dFdC	Cytotoxicity against human CFPAC-1 cells assessed as reduction of cell survival after 72 hrs by MTT assay Cytotoxicity against human CFPAC-1 cells assessed as reduction of cell survival after 72 hrs by MTT assay	[PMID: 24631359]
COLO 205	IC₅₀	0.0514 μM Compound: Gemcitabine	Antiproliferative activity against p53 deficient human COLO205 cells after 72 hrs Antiproliferative activity against p53 deficient human COLO205 cells after 72 hrs	[PMID: 18469809]
COLO 205	IC₅₀	3 μM Compound: Gemcitabine	Antiproliferative activity against human p53 deficient COLO205 cells after 72 hrs by celltiter-glo assay Antiproliferative activity against human p53 deficient COLO205 cells after 72 hrs by celltiter-glo assay	[PMID: 20873740]
COLO 205	IC₅₀	3.24 μM Compound: 7	Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay	[PMID: 23968824]
COLO 320DM	IC₅₀	3.92 μM Compound: 7	Cytotoxicity against human COLO320DM cells after 48 hrs by MTT assay Cytotoxicity against human COLO320DM cells after 48 hrs by MTT assay	[PMID: 23968824]
COLO357	IC₅₀	0.36 nM Compound: GEM	Cytotoxicity against human Colo-357 cells by crystal violet staining Cytotoxicity against human Colo-357 cells by crystal violet staining	[PMID: 20930123]
CT26	IC₅₀	0.006 μM Compound: Gemcitabine	Cytotoxicity against mouse CT26 cells after 3 days by MTT assay Cytotoxicity against mouse CT26 cells after 3 days by MTT assay	[PMID: 21711054]
CV-1	IC₅₀	21.9 μM Compound: Gemcitabine	Cytotoxicity against african green monkey CV1 cells after 72 hrs by MTT assay Cytotoxicity against african green monkey CV1 cells after 72 hrs by MTT assay	[PMID: 23489626]
DAN-G	IC₅₀	3.4 nM Compound: GEM	Cytotoxicity against human DAN-G cells by crystal violet staining Cytotoxicity against human DAN-G cells by crystal violet staining	[PMID: 20930123]
DMS-53	IC₅₀	0.009 μM Compound: gemcitabine	Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay	[PMID: 22861499]
DU-145	IC₅₀	0.0356 μM Compound: gemcitabine	In vitro cytotoxic activity against prostate carcinoma (DU-145) cells assayed by inhibition of [3H]-labeled thymidine incorporation In vitro cytotoxic activity against prostate carcinoma (DU-145) cells assayed by inhibition of [3H]-labeled thymidine incorporation	[PMID: 11728191]
DU-145	IC₅₀	213 nM Compound: dFdC	Antiproliferative activity against human DU145 cells measured after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells measured after 72 hrs by MTT assay	[PMID: 30716713]
DU-145	IC₅₀	3.5 nM Compound: gemcitabine	Antiproliferative activity against human DU145 cells by MTT assay Antiproliferative activity against human DU145 cells by MTT assay	[PMID: 17887663]
DU-145	IC₅₀	399 nM Compound: Gemcitabine	Antiproliferative activity against human DU-145 cells measured after 72 hrs by MTT assay Antiproliferative activity against human DU-145 cells measured after 72 hrs by MTT assay	[PMID: 33223264]
EL4	IC₅₀	0.007 μM Compound: Gemcitabine	Cytotoxicity against mouse EL4 cells after 3 days by MTT assay Cytotoxicity against mouse EL4 cells after 3 days by MTT assay	[PMID: 21711054]
FTC-133	IC₅₀	3.36 μM Compound: Gemcitabine	Cytotoxicity against human FTC-133 cells after 24 hrs by MTT assay Cytotoxicity against human FTC-133 cells after 24 hrs by MTT assay	[PMID: 24436994]
HCT-116	IC₅₀	0.005 μM Compound: gemcitabine	Cytotoxicity against human HCT116 cells by sulforhodamine B method Cytotoxicity against human HCT116 cells by sulforhodamine B method	[PMID: 19691349]
HCT-116	IC₅₀	0.006 μM Compound: Gemcitabine	Antiproliferative activity against human HCT116 cells expressing p53 after 72 hrs by celltiter-glo assay Antiproliferative activity against human HCT116 cells expressing p53 after 72 hrs by celltiter-glo assay	[PMID: 20873740]
HCT-116	IC₅₀	0.0097 μM Compound: Gemcitabine	Antiproliferative activity against human HCT116 cells expressing p53 gene after 72 hrs by proliferative assay Antiproliferative activity against human HCT116 cells expressing p53 gene after 72 hrs by proliferative assay	[PMID: 18469809]
HCT-116	IC₅₀	0.03 μM Compound: Gemcitabine	Antiproliferative activity against human HCT116 cells after 3 days by MTS assay Antiproliferative activity against human HCT116 cells after 3 days by MTS assay	[PMID: 30281308]
HCT-116	IC₅₀	0.03 μM Compound: Gemcitabine	Cytostatic activity against human HCT116 cells after 3 days by MTS assay Cytostatic activity against human HCT116 cells after 3 days by MTS assay	[PMID: 30108897]
HCT-116	IC₅₀	0.03 μM Compound: Gemcitabine	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 28221790]
HCT-116	IC₅₀	0.05 μM Compound: Gem	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35300092]
HCT-116	IC₅₀	0.32 μM Compound: Gemcitabine	Cytotoxicity against human HCT116 cells after 48 hrs by WST-8 assay Cytotoxicity against human HCT116 cells after 48 hrs by WST-8 assay	[PMID: 22342146]
HCT-116	IC₅₀	0.41 μM Compound: Gemcitabine	Antiproliferative activity against p53 gene knocked out human HCT116 cells after 3 days by MTS assay Antiproliferative activity against p53 gene knocked out human HCT116 cells after 3 days by MTS assay	[PMID: 30281308]
HCT-116	IC₅₀	0.41 μM Compound: Gemcitabine	Cytostatic activity against human HCT116 p53-/- cells after 3 days by MTS assay Cytostatic activity against human HCT116 p53-/- cells after 3 days by MTS assay	[PMID: 30108897]
HCT-116	IC₅₀	0.41 μM Compound: Gemcitabine	Cytotoxicity against p53 deficient human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against p53 deficient human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 28221790]
HCT-116	IC₅₀	14.3 μM Compound: gemzar, gemcitabine	Cytotoxicity against multidrug-resistant human HCT116 cells by thymidine incorporation assay Cytotoxicity against multidrug-resistant human HCT116 cells by thymidine incorporation assay	[PMID: 18186604]
HCT-116	IC₅₀	30 nM Compound: Gemcitabine	Growth inhibition of human HCT116 cells after 72 hrs by Hoechst 33258 dye based fluorescence assay Growth inhibition of human HCT116 cells after 72 hrs by Hoechst 33258 dye based fluorescence assay	[PMID: 29253340]
HCT-116	IC₅₀	7.33 μM Compound: 7	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C5MD00158G
HCT-15	GI₅₀	0.003 μM Compound: gemcitabine	Cytotoxicity against human HCT15 cells after 5 days by SRB assay Cytotoxicity against human HCT15 cells after 5 days by SRB assay	[PMID: 19929004]
HCT-15	IC₅₀	0.0099 μM Compound: Gemcitabine	Antiproliferative activity against human HCT15 cells expressing p53 gene after 72 hrs by proliferative assay Antiproliferative activity against human HCT15 cells expressing p53 gene after 72 hrs by proliferative assay	[PMID: 18469809]
HCT-15	IC₅₀	0.01 μM Compound: Gemcitabine	Antiproliferative activity against human HCT15 cells expressing p53 after 72 hrs by celltiter-glo assay Antiproliferative activity against human HCT15 cells expressing p53 after 72 hrs by celltiter-glo assay	[PMID: 20873740]
HCT-15	IC₅₀	11.8 μM Compound: gemzar, gemcitabine	Cytotoxicity against multidrug-resistant human HCT15 cells by thymidine incorporation assay Cytotoxicity against multidrug-resistant human HCT15 cells by thymidine incorporation assay	[PMID: 18186604]
HCT-8	IC₅₀	1.74 μM Compound: Gemcitabine	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 19362474]
HEK293	IC₅₀	0.05 μM Compound: Gemcitabine	Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35439009]
HEL	CC₅₀	0.0036 μM Compound: Gemcitabine	Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis	[PMID: 33479570]
HEL	IC₅₀	0.48 μM Compound: Gemcitabine	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 27670098]
HeLa	IC₅₀	> 10 μM Compound: Gemcitabine	Antiproliferative activity against human p53 deficient HeLa cells after 72 hrs by celltiter-glo assay Antiproliferative activity against human p53 deficient HeLa cells after 72 hrs by celltiter-glo assay	[PMID: 20873740]
HeLa	IC₅₀	> 10 μM Compound: Gemcitabine	Antiproliferative activity against p53 deficient human HeLa cells after 72 hrs Antiproliferative activity against p53 deficient human HeLa cells after 72 hrs	[PMID: 18469809]
HeLa	IC₅₀	0.0099 μM Compound: 2a, dFdC, Gemcitabine	Cytostatic activity against human HeLa cells after 4 days by coulter counter analysis Cytostatic activity against human HeLa cells after 4 days by coulter counter analysis	[PMID: 24341356]
HeLa	IC₅₀	0.05 μM Compound: Gemcitabine, Gemzar	Cytotoxicity against human HeLa cells after 72 hrs by resazurin assay Cytotoxicity against human HeLa cells after 72 hrs by resazurin assay	[PMID: 22944119]
HeLa	IC₅₀	0.9 μM Compound: Gemcitabine, dFdC	Cytotoxicity against human HeLa cells assessed as reduction of cell survival after 96 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction of cell survival after 96 hrs by MTT assay	[PMID: 24631359]
HeLa	IC₅₀	10 μM Compound: Gemcitabine, dFdC	Cytotoxicity against human HeLa cells assessed as reduction of cell survival after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction of cell survival after 72 hrs by MTT assay	[PMID: 24631359]
HeLa	IC₅₀	2.74 μM Compound: Gemcitabine	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27670098]
HeLa	IC₅₀	3.3 μM Compound: Gemcitabine	Cytotoxicity against human HeLa cells after 24 hrs by MTT colorimetric assay Cytotoxicity against human HeLa cells after 24 hrs by MTT colorimetric assay	[PMID: 25703296]
HeLa	IC₅₀	4.12 μM Compound: Gemcitabine	Cytotoxicity against human HeLa cells after 3 days by MTT assay Cytotoxicity against human HeLa cells after 3 days by MTT assay	[PMID: 21711054]
HeLa	IC₅₀	9.42 μM Compound: 1; dFdC	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
HepG2	IC₅₀	2.97 μM Compound: 7	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C5MD00158G
HepG2	IC₅₀	4.9 μM Compound: 1; dFdC	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
HFF-1	IC₅₀	14.38 μM Compound: Gemcitabine	Cytotoxicity against human HFF-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HFF-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35439009]
HPAC	IC₅₀	0.073 μM Compound: Gemcitabine	Cytotoxicity against human HPAC cells after 3 days by MTT assay Cytotoxicity against human HPAC cells after 3 days by MTT assay	[PMID: 21711054]
HT-29	IC₅₀	> 100 μM Compound: 1; dFdC	Antiproliferative activity against human HT-29 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HT-29 cells after 48 hrs by sulforhodamine B assay	[PMID: 28495087]
HT-29	IC₅₀	0.003 μM Compound: gemcitabine	In vitro cytotoxic activity against colon adenocarcinoma (HT-29) cells assayed by inhibition of [3H]-labeled thymidine incorporation In vitro cytotoxic activity against colon adenocarcinoma (HT-29) cells assayed by inhibition of [3H]-labeled thymidine incorporation	[PMID: 11728191]
HT-29	GI₅₀	0.03 μM Compound: gemcitabine	Antitumor activity against human HT29 cells after 48 hrs by MTS assay Antitumor activity against human HT29 cells after 48 hrs by MTS assay	[PMID: 18588281]
HT-29	IC₅₀	0.52 μM Compound: Gemcitabine	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 26025875]
HT-29	IC₅₀	1.53 μM Compound: Gemcitabine	Cytotoxicity against human HT-29 cells after 3 days by MTT assay Cytotoxicity against human HT-29 cells after 3 days by MTT assay	[PMID: 21711054]
HT-29	IC₅₀	1.95 μM Compound: 7	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 23968824]
Huh-7	CC₅₀	< 0.1 μM Compound: 11	Cytotoxicity against human HuH7 cells by MTS assay Cytotoxicity against human HuH7 cells by MTS assay	[PMID: 20580554]
HUVEC	IC₅₀	0.003 μM Compound: Gemcitabine, dFdC	Cytotoxicity against HUVEC assessed as cell after 48 hrs by MTT assay Cytotoxicity against HUVEC assessed as cell after 48 hrs by MTT assay	[PMID: 24631359]
Jurkat	EC₅₀	0.023 μM Compound: 11	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
Jurkat	IC₅₀	0.03 μM Compound: Gemcitabine	Antiproliferative activity against human p53 deficient Jurkat cells after 72 hrs by celltiter-glo assay Antiproliferative activity against human p53 deficient Jurkat cells after 72 hrs by celltiter-glo assay	[PMID: 20873740]
Jurkat	IC₅₀	0.0453 μM Compound: Gemcitabine	Antiproliferative activity against p53 deficient human Jurkat cells after 72 hrs by proliferative assay Antiproliferative activity against p53 deficient human Jurkat cells after 72 hrs by proliferative assay	[PMID: 18469809]
K562	IC₅₀	0.006 μM Compound: Gemcitabine	Cytotoxicity against human paclitaxel resistant K562 cells after 3 days by MTT assay Cytotoxicity against human paclitaxel resistant K562 cells after 3 days by MTT assay	[PMID: 21711054]
K562	IC₅₀	0.05 μM Compound: Gemcitabine, dFdC	Cytotoxicity against human K562 cells assessed as reduction of cell survival after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction of cell survival after 48 hrs by MTT assay	[PMID: 24631359]
K562	IC₅₀	0.1 μM Compound: Gemcitabine	Antiproliferative activity against human K562 cells after 3 days by MTS assay Antiproliferative activity against human K562 cells after 3 days by MTS assay	[PMID: 30281308]
K562	IC₅₀	0.1 μM Compound: Gemcitabine	Cytostatic activity against human K562 cells after 3 days by MTS assay Cytostatic activity against human K562 cells after 3 days by MTS assay	[PMID: 30108897]
K562	IC₅₀	0.1 μM Compound: Gemcitabine	Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 28221790]
K562	IC₅₀	0.11 μM Compound: Gemcitabine	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 27670098]
K562	GI₅₀	0.32 μM Compound: gemcitabine	Antitumor activity against human K562 cells after 48 hrs by MTS assay Antitumor activity against human K562 cells after 48 hrs by MTS assay	[PMID: 18588281]
K562	IC₅₀	0.6 μM Compound: Gemcitabine	Antiproliferative activity against human p53 deficient K562 cells after 72 hrs by celltiter-glo assay Antiproliferative activity against human p53 deficient K562 cells after 72 hrs by celltiter-glo assay	[PMID: 20873740]
K562	IC₅₀	0.718 μM Compound: Gemcitabine	Cytotoxicity against human K562 cells after 3 days by MTT assay Cytotoxicity against human K562 cells after 3 days by MTT assay	[PMID: 21711054]
K562	IC₅₀	0.7459 μM Compound: Gemcitabine	Antiproliferative activity against p53 deficient human K562 cells after 72 hrs Antiproliferative activity against p53 deficient human K562 cells after 72 hrs	[PMID: 18469809]
KB	IC₅₀	8.21 μM Compound: 1; dFdC	Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
KG-1	IC₅₀	0.0018 μM Compound: Gem	Antiproliferative activity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35300092]
KG-1	IC₅₀	0.86 μM Compound: Gemcitabine	Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay	[PMID: 27670098]
L02	IC₅₀	> 20 μM Compound: GCT	Antiproliferative activity against human LO2 cells after 72 hrs by CCK8 assay Antiproliferative activity against human LO2 cells after 72 hrs by CCK8 assay	[PMID: 28576633]
L02	IC₅₀	5.43 μM Compound: Gemcitabine	Antiproliferative activity against human HL7702 cells after 48 hrs by MTT assay Antiproliferative activity against human HL7702 cells after 48 hrs by MTT assay	[PMID: 27670098]
L1210	IC₅₀	0.007 μM Compound: Gemcitabine	Cytotoxicity against mouse L1210 cells after 3 days by MTT assay Cytotoxicity against mouse L1210 cells after 3 days by MTT assay	[PMID: 21711054]
L1210	IC₅₀	0.013 μM Compound: 2a, dFdC, Gemcitabine	Cytostatic activity against mouse L1210 cells after 2 days by coulter counter analysis Cytostatic activity against mouse L1210 cells after 2 days by coulter counter analysis	[PMID: 24341356]
L1210	IC₅₀	0.013 μM Compound: 1, dFdC, GEM, Gemcitabine	Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counter analysis Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counter analysis	[PMID: 24471998]
LNCaP	IC₅₀	0.512 μM Compound: Gemcitabine	Cytotoxicity against human LNCAP cells after 3 days by MTT assay Cytotoxicity against human LNCAP cells after 3 days by MTT assay	[PMID: 21711054]
MCF-10A	IC₅₀	> 10 μM Compound: Gemcitabine	Cytotoxicity against human MCF10A cells after 48 hrs by WST-8 assay Cytotoxicity against human MCF10A cells after 48 hrs by WST-8 assay	[PMID: 22342146]
MCF7	IC₅₀	0.0072 μM Compound: 2a, dFdC, Gemcitabine	Cytostatic activity against human MCF7 cells after 2 days by coulter counter analysis Cytostatic activity against human MCF7 cells after 2 days by coulter counter analysis	[PMID: 24341356]
MCF7	GI₅₀	0.01 μM Compound: gemcitabine	Antitumor activity against human MCF7 cells after 48 hrs by MTS assay Antitumor activity against human MCF7 cells after 48 hrs by MTS assay	[PMID: 18588281]
MCF7	IC₅₀	0.06 μM Compound: Gemcitabine, Gemzar	Cytotoxicity against human MCF7 cells after 72 hrs by resazurin assay Cytotoxicity against human MCF7 cells after 72 hrs by resazurin assay	[PMID: 22944119]
MCF7	IC₅₀	0.08 μM Compound: Gemcitabine	Antiproliferative activity against human MCF7 cells expressing p53 after 72 hrs by celltiter-glo assay Antiproliferative activity against human MCF7 cells expressing p53 after 72 hrs by celltiter-glo assay	[PMID: 20873740]
MCF7	IC₅₀	0.0803 μM Compound: Gemcitabine	Antiproliferative activity against human MCF7 cells expressing p53 gene after 72 hrs by proliferative assay Antiproliferative activity against human MCF7 cells expressing p53 gene after 72 hrs by proliferative assay	[PMID: 18469809]
MCF7	IC₅₀	0.149 μM Compound: Gemcitabine	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 21711054]
MCF7	IC₅₀	0.15 μM Compound: Gemcitabine	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 26025875]
MCF7	IC₅₀	0.57 μM Compound: Gemcitabine	Cytotoxicity against human MCF7 cells incubated for 72 hrs under normoxic condition by MTT assay Cytotoxicity against human MCF7 cells incubated for 72 hrs under normoxic condition by MTT assay	[PMID: 28075592]
MCF7	IC₅₀	1.4 nM Compound: 1; dFdC	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 33479633]
MCF7	IC₅₀	3.28 μM Compound: Gemcitabine	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19362474]
MCF7	IC₅₀	38 nM Compound: dFdC	Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay	[PMID: 30716713]
MCF7	IC₅₀	6.1 μM Compound: Gemcitabine	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33964437]
MCF7	IC₅₀	8.9 μM Compound: Gemcitabine	Cytotoxicity against human MCF7 cells incubated for 72 hrs under hypoxic condition by MTT assay Cytotoxicity against human MCF7 cells incubated for 72 hrs under hypoxic condition by MTT assay	[PMID: 28075592]
MDA-MB-231	IC₅₀	> 10 μM Compound: gemcitabine	Antiproliferative activity against gemcitabine-resistant human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against gemcitabine-resistant human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 25350923]
MDA-MB-231	IC₅₀	0.025 μM Compound: gemcitabine	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 25350923]
MDA-MB-231	IC₅₀	0.19 μM Compound: Gemcitabine	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT colorimetric assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT colorimetric assay	[PMID: 25703296]
MDA-MB-231	IC₅₀	0.245 μM Compound: Gemcitabine	Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay	[PMID: 21711054]
MDA-MB-231	IC₅₀	0.65 μM Compound: Gemcitabine	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 26025875]
MDA-MB-231	IC₅₀	1.15 μM Compound: Gemcitabine	Cytotoxicity against human MDA-MB-231 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay Cytotoxicity against human MDA-MB-231 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay	[PMID: 33359608]
MDA-MB-231	IC₅₀	1.67 μM Compound: Gemcitabine	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 27670098]
MDA-MB-231	IC₅₀	11.4 nM Compound: gemcitabine	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 17887663]
MDA-MB-231	IC₅₀	1567 nM Compound: dFdC	Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay	[PMID: 30716713]
MDA-MB-231	IC₅₀	2.1 μM Compound: Gemcitabine	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	2.22 μM Compound: Gemcitabine	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 35217359]
MDA-MB-231	IC₅₀	30 nM Compound: Gemcitabine	Growth inhibition of human MDA-MB-231 cells after 72 hrs by Hoechst 33258 dye based fluorescence assay Growth inhibition of human MDA-MB-231 cells after 72 hrs by Hoechst 33258 dye based fluorescence assay	[PMID: 29253340]
MDA-MB-231	IC₅₀	36.4 nM Compound: Gemcitabine	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29795767]
MDA-MB-231	IC₅₀	61.5 nM Compound: Gemcitabine	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay	[PMID: 35737669]
MDA-MB-231	IC₅₀	7.21 μM Compound: GEM	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth pretreated with hENT1 inhibitor, dipyridamole at 10 uM followed by compound addition Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth pretreated with hENT1 inhibitor, dipyridamole at 10 uM followed by compound addition	[PMID: 35810950]
MDA-MB-231	IC₅₀	8 μM Compound: Gemcitabine	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33964437]
MES-SA	IC₅₀	0.005 μM Compound: Gemcitabine	Cytotoxicity against human MES-SA cells after 3 days by MTT assay Cytotoxicity against human MES-SA cells after 3 days by MTT assay	[PMID: 21711054]
MES-SA/Dx5	IC₅₀	0.0092 μM Compound: gemcitabine	In vitro cytotoxic activity against uterine sarcoma (MES-SA) cells assayed by inhibition of [3H]-labeled thymidine incorporation In vitro cytotoxic activity against uterine sarcoma (MES-SA) cells assayed by inhibition of [3H]-labeled thymidine incorporation	[PMID: 11728191]
MIA PaCa-2	EC₅₀	0.0015 μM Compound: Gemcitabine	Antiproliferative activity against human MIA PaCa-2 cells assessed as cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MIA PaCa-2 cells assessed as cell viability measured after 72 hrs by MTT assay	[PMID: 28105281]
MIA PaCa-2	IC₅₀	0.016 μM Compound: Gemcitabine	Cytotoxicity against human MIAPaCa2 cells incubated for 24 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells incubated for 24 hrs by MTT assay	[PMID: 30904782]
MIA PaCa-2	IC₅₀	0.06 μM Compound: Gemcitabine, Gemzar	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by resazurin assay Cytotoxicity against human MIAPaCa2 cells after 72 hrs by resazurin assay	[PMID: 22944119]
MIA PaCa-2	IC₅₀	0.11 μM Compound: Gemcitabine	Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35439009]
MIA PaCa-2	IC₅₀	0.11 μM Compound: Gemcitabine	Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell proliferation after 72 hrs by MTT assay	[PMID: 29328656]
MIA PaCa-2	IC₅₀	0.12 μM Compound: Gemcitabine	Antiproliferative activity against human MIAPaCa2 cells after 70 hrs by alamar blue assay Antiproliferative activity against human MIAPaCa2 cells after 70 hrs by alamar blue assay	[PMID: 29471119]
MIA PaCa-2	IC₅₀	0.23 μM Compound: Gemcitabine	Cytotoxicity against human MIA PaCa-2 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay Cytotoxicity against human MIA PaCa-2 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay	[PMID: 33359608]
MIA PaCa-2	IC₅₀	0.36 μM Compound: Gemcitabine	Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 35217359]
MIA PaCa-2	IC₅₀	0.6 μM Compound: Gemcitabine	Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT colorimetric assay Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT colorimetric assay	[PMID: 25703296]
MIA PaCa-2	IC₅₀	1.04 μM Compound: 1, dFdC, GEM, Gemcitabine	Cytostatic activity against human MIAPaCa2 cells after 72 hrs by MTS assay Cytostatic activity against human MIAPaCa2 cells after 72 hrs by MTS assay	[PMID: 24471998]
MIA PaCa-2	EC₅₀	2 μM Compound: 1	Cytotoxicity against human MIAPaCa2 cells after 5 days by PrestoBlue assay Cytotoxicity against human MIAPaCa2 cells after 5 days by PrestoBlue assay	[PMID: 24867590]
MIA PaCa-2	IC₅₀	3.3 μM Compound: Gemcitabine	Cytotoxicity against gemcitabine-resistant human MIAPaCa2 cells assessed as decrease in cell proliferation after 72 hrs by MTT assay Cytotoxicity against gemcitabine-resistant human MIAPaCa2 cells assessed as decrease in cell proliferation after 72 hrs by MTT assay	[PMID: 29328656]
MIA PaCa-2	GI₅₀	35.83 nM Compound: Gem	Growth inhibition of human MIAPaCa2 cells after 48 hrs by SRB assay Growth inhibition of human MIAPaCa2 cells after 48 hrs by SRB assay	[PMID: 23094992]
MIA PaCa-2	GI₅₀	35.83 μM Compound: Gem	Growth inhibition of human MIAPaCa2 cells after 48 hrs by SRB assay Growth inhibition of human MIAPaCa2 cells after 48 hrs by SRB assay	[PMID: 22512908]
MKN-28	IC₅₀	> 100 μM Compound: 1; dFdC	Antiproliferative activity against human MKN28 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MKN28 cells after 48 hrs by sulforhodamine B assay	[PMID: 28495087]
MRC5	IC₅₀	< 0.0039 μM Compound: 1, gemcitabine, GEM, dFdC	Cytotoxicity against human MRC5 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid Cytotoxicity against human MRC5 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid	[PMID: 25874330]
MRC5	IC₅₀	< 0.0039 μM Compound: 1, gemcitabine, GEM, dFdC	Cytotoxicity against human MRC5 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid Cytotoxicity against human MRC5 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid	[PMID: 25874330]
MRC5	IC₅₀	> 50 μM Compound: Gemcitabine	Antiproliferative activity against human MRC5 cells after 3 days by MTS assay Antiproliferative activity against human MRC5 cells after 3 days by MTS assay	[PMID: 30281308]
MRC5	IC₅₀	> 50 μM Compound: Gemcitabine	Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 28221790]
MRC5	IC₅₀	0.0063 μM Compound: 1, gemcitabine, GEM, dFdC	Cytotoxicity against human MRC5 cells after 48 hrs by SRB assay Cytotoxicity against human MRC5 cells after 48 hrs by SRB assay	[PMID: 25874330]
MRC5	IC₅₀	0.0068 μM Compound: 1, gemcitabine, GEM, dFdC	Cytotoxicity against human MRC5 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid Cytotoxicity against human MRC5 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid	[PMID: 25874330]
MRC5	IC₅₀	0.0216 μM Compound: 1, gemcitabine, GEM, dFdC	Cytotoxicity against human MRC5 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid Cytotoxicity against human MRC5 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid	[PMID: 25874330]
MRC5	IC₅₀	35.1 μM Compound: Gemcitabine	Cytotoxicity against human MRC5 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay Cytotoxicity against human MRC5 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay	[PMID: 34342431]
MRC5	IC₅₀	80 μM Compound: Gemcitabine	Antiproliferative activity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33964437]
NCI-H146	IC₅₀	2.78 μM Compound: Gemcitabine	Cytotoxicity against human NCI-H146 cells after 3 days by MTT assay Cytotoxicity against human NCI-H146 cells after 3 days by MTT assay	[PMID: 21711054]
NCI-H1975	IC₅₀	> 10 μM Compound: GCT	Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells harboring FAK after 72 hrs by CCK8 assay Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells harboring FAK after 72 hrs by CCK8 assay	[PMID: 28576633]
NCI-H23	GI₅₀	0.002 μM Compound: gemcitabine	Cytotoxicity against human NCI-H23 cells after 5 days by SRB assay Cytotoxicity against human NCI-H23 cells after 5 days by SRB assay	[PMID: 19929004]
NCI-H460	IC₅₀	0.0078 μM Compound: gemcitabine	In vitro cytotoxic activity against nonsmall cell lung carcinoma (NCI-H460) cells assayed by inhibition of [3H]-labeled thymidine incorporation In vitro cytotoxic activity against nonsmall cell lung carcinoma (NCI-H460) cells assayed by inhibition of [3H]-labeled thymidine incorporation	[PMID: 11728191]
NCI-H460	IC₅₀	0.23 μM Compound: Gemcitabine	Cytotoxicity against human NCI-H460 cells after 48 hrs by WST-8 assay Cytotoxicity against human NCI-H460 cells after 48 hrs by WST-8 assay	[PMID: 22342146]
NCI-H460	IC₅₀	10 nM Compound: dFdc	Growth inhibition of H460 cells by SRB assay Growth inhibition of H460 cells by SRB assay	[PMID: 17602464]
NCI-H460	IC₅₀	103 nM Compound: dFdc	Growth inhibition of H460 cells by SRB assay in presence of dipyridamole Growth inhibition of H460 cells by SRB assay in presence of dipyridamole	[PMID: 17602464]
NHDF	IC₅₀	0.02 μM Compound: Gemcitabine	Antiproliferative activity against NHDF expressing p53 after 72 hrs by celltiter-glo assay Antiproliferative activity against NHDF expressing p53 after 72 hrs by celltiter-glo assay	[PMID: 20873740]
NHDF	IC₅₀	0.0221 μM Compound: Gemcitabine	Antiproliferative activity against NHDF expressing p53 gene after 72 hrs by proliferative assay Antiproliferative activity against NHDF expressing p53 gene after 72 hrs by proliferative assay	[PMID: 18469809]
NHDF	IC₅₀	19.45 μM Compound: 1; dFdC	Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
OVCAR-8	IC₅₀	0.0026 μM Compound: Gemcitabine	Antiproliferative activity against p53 deficient human OVCAR8 cells after 72 hrs by proliferative assay Antiproliferative activity against p53 deficient human OVCAR8 cells after 72 hrs by proliferative assay	[PMID: 18469809]
OVCAR-8	IC₅₀	0.003 μM Compound: Gemcitabine	Antiproliferative activity against human p53 deficient OVCAR8 cells after 72 hrs by celltiter-glo assay Antiproliferative activity against human p53 deficient OVCAR8 cells after 72 hrs by celltiter-glo assay	[PMID: 20873740]
P388D1	IC₅₀	0.019 μM Compound: Gemcitabine	Cytotoxicity against mouse P388D1 cells after 3 days by MTT assay Cytotoxicity against mouse P388D1 cells after 3 days by MTT assay	[PMID: 21711054]
PANC-1	IC₅₀	> 100 μM Compound: Gem	Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability incubated for 24 hrs in nutrient-rich Dulbecco's modified Eagle's medium by WST-8 assay Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability incubated for 24 hrs in nutrient-rich Dulbecco's modified Eagle's medium by WST-8 assay	[PMID: 35969895]
PANC-1	EC₅₀	> 2000 μM Compound: 1, dFdC, GEM, Gemcitabine	Cytotoxicity against human PANC1 cells assessed as cell viability by MTT assay in presence of hENT1 inhibitor dipyridamole Cytotoxicity against human PANC1 cells assessed as cell viability by MTT assay in presence of hENT1 inhibitor dipyridamole	[PMID: 24471998]
PANC-1	IC₅₀	> 50 μM Compound: Gemcitabine	Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay	[PMID: 23489626]
PANC-1	IC₅₀	> 500 μM Compound: Gemcitabine	Cytotoxicity against human PANC1 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay Cytotoxicity against human PANC1 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay	[PMID: 32920143]
PANC-1	IC₅₀	0.022 μM Compound: Gemcitabine	Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 32736230]
PANC-1	IC₅₀	0.11 μM Compound: Gemcitabine	Cytotoxicity against human PANC1 cells after 48 hrs by WST-8 assay Cytotoxicity against human PANC1 cells after 48 hrs by WST-8 assay	[PMID: 22342146]
PANC-1	IC₅₀	0.15 μM Compound: Gemcitabine	Antiproliferative activity against human Panc-1 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human Panc-1 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32007666]
PANC-1	IC₅₀	0.16 μM Compound: 1d	Antimigratory activity against human PANC1 cells measured after 18 hrs in presence of mitomycin C using crystal violet staining by inverted microscopy-based transwell assay Antimigratory activity against human PANC1 cells measured after 18 hrs in presence of mitomycin C using crystal violet staining by inverted microscopy-based transwell assay	[PMID: 31026162]
PANC-1	IC₅₀	0.16 μM Compound: 1d	Antiinvasive activity against human PANC1 cells measured after 18 hrs in presence of mitomycin C using crystal violet staining by inverted microscopy-based matrigel coated transwell assay Antiinvasive activity against human PANC1 cells measured after 18 hrs in presence of mitomycin C using crystal violet staining by inverted microscopy-based matrigel coated transwell assay	[PMID: 31026162]
PANC-1	IC₅₀	0.2 μM Compound: Gemcitabine	Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35439009]
PANC-1	IC₅₀	0.4 μM Compound: Gemcitabine	Cytotoxicity against human PANC1 cells after 72 hrs under normoxic condition by MTT assay Cytotoxicity against human PANC1 cells after 72 hrs under normoxic condition by MTT assay	[PMID: 29656202]
PANC-1	IC₅₀	1 nM Compound: GEM	Cytotoxicity against human PANC1 cells by crystal violet staining Cytotoxicity against human PANC1 cells by crystal violet staining	[PMID: 20930123]
PANC-1	IC₅₀	1.7 μM Compound: Gemcitabine	Cytotoxicity against human PANC1 cells after 72 hrs under hypoxic condition by MTT assay Cytotoxicity against human PANC1 cells after 72 hrs under hypoxic condition by MTT assay	[PMID: 29656202]
PANC-1	IC₅₀	10.988 μM Compound: Gemcitabine	Cytotoxicity against human PANC1 cells incubated for 24 hrs by MTT assay Cytotoxicity against human PANC1 cells incubated for 24 hrs by MTT assay	[PMID: 30904782]
PANC-1	IC₅₀	30 μM Compound: Gemcitabine	Cytotoxicity against human PANC-1 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay Cytotoxicity against human PANC-1 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay	[PMID: 34342431]
PANC-1	IC₅₀	30.4 μM Compound: GCT	Antiproliferative activity against human PANC1 cells after 72 hrs by CCK8 assay Antiproliferative activity against human PANC1 cells after 72 hrs by CCK8 assay	[PMID: 28576633]
PANC-1	IC₅₀	4.2 μM Compound: Gemcitabine	Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33964437]
PANC-1	IC₅₀	5.6 μM Compound: Gemcitabine	Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay	[PMID: 19362474]
PANC-1	GI₅₀	5.8 μM Compound: Gemcitabine	Growth inhibition of human PANC1 cells after 72 hrs by WST8 assay Growth inhibition of human PANC1 cells after 72 hrs by WST8 assay	[PMID: 28495081]
PANC-1	IC₅₀	5.9 μM Compound: Gemcitabine	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by WST-8 assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by WST-8 assay	[PMID: 31967821]
PANC-1	EC₅₀	611 μM Compound: 1, dFdC, GEM, Gemcitabine	Cytotoxicity against human PANC1 cells assessed as cell viability by MTT assay in absence of hENT1 inhibitor dipyridamole Cytotoxicity against human PANC1 cells assessed as cell viability by MTT assay in absence of hENT1 inhibitor dipyridamole	[PMID: 24471998]
PANC-1	IC₅₀	8.3 μM Compound: GEM	Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35380848]
PaTu 8988t	IC₅₀	2.8 nM Compound: GEM	Cytotoxicity against human Patu-T cells by crystal violet staining Cytotoxicity against human Patu-T cells by crystal violet staining	[PMID: 20930123]
PC-3	IC₅₀	0.0026 μM Compound: Gemcitabine	Antiproliferative activity against human PC3 cells expressing p53 gene after 72 hrs by proliferative assay Antiproliferative activity against human PC3 cells expressing p53 gene after 72 hrs by proliferative assay	[PMID: 18469809]
PC-3	IC₅₀	0.003 μM Compound: Gemcitabine	Antiproliferative activity against human p53 deficient PC3 cells after 72 hrs by celltiter-glo assay Antiproliferative activity against human p53 deficient PC3 cells after 72 hrs by celltiter-glo assay	[PMID: 20873740]
PC-3	GI₅₀	0.006 μM Compound: gemcitabine	Cytotoxicity against human PC3 cells after 5 days by SRB assay Cytotoxicity against human PC3 cells after 5 days by SRB assay	[PMID: 19929004]
PC-3	IC₅₀	0.04 μM Compound: gemcitabine	Cytotoxicity against human PC3 cells by sulforhodamine B method Cytotoxicity against human PC3 cells by sulforhodamine B method	[PMID: 19691349]
PC-3	EC₅₀	0.065 μM Compound: 11	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
PC-3	IC₅₀	0.22 μM Compound: Gemcitabine	Antiproliferative activity against human PC-3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC-3 cells after 48 hrs by MTT assay	[PMID: 27670098]
PC-3	IC₅₀	416 nM Compound: dFdC	Antiproliferative activity against human PC3 cells measured after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells measured after 72 hrs by MTT assay	[PMID: 30716713]
PC-3	IC₅₀	546 nM Compound: Gemcitabine	Antiproliferative activity against human PC-3 cells measured after 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells measured after 72 hrs by MTT assay	[PMID: 33223264]
PC-3	IC₅₀	74 nM Compound: 1; dFdC	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 33479633]
PLC-PRF-5	IC₅₀	1.53 μM Compound: Gemcitabine	Antiproliferative activity against human PLC-PRF-5 cells after 48 hrs by MTT assay Antiproliferative activity against human PLC-PRF-5 cells after 48 hrs by MTT assay	[PMID: 27670098]
PSN1	IC₅₀	0.005 μM Compound: 19	Antiproliferative activity against human PSN1 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay Antiproliferative activity against human PSN1 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay	[PMID: 32858470]
Ramos	IC₅₀	> 10 μM Compound: GCT	Antiproliferative activity against human Ramos cells after 72 hrs by CCK8 assay Antiproliferative activity against human Ramos cells after 72 hrs by CCK8 assay	[PMID: 28576633]
Ramos	EC₅₀	0.00003 μM Compound: 11	Cytotoxicity against human Ramos cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human Ramos cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
RT-112	EC₅₀	1.4 nM Compound: 1, dFdC, GEM, Gemcitabine	Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in absence of dCK substrate deoxycytidine Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in absence of dCK substrate deoxycytidine	[PMID: 24471998]
RT-112	EC₅₀	104.9 nM Compound: 1, dFdC, GEM, Gemcitabine	Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in presence of dCK substrate deoxycytidine Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in presence of dCK substrate deoxycytidine	[PMID: 24471998]
SF-268	IC₅₀	0.01 μM Compound: Gemcitabine	Antiproliferative activity against human p53 deficient SF268 cells after 72 hrs by celltiter-glo assay Antiproliferative activity against human p53 deficient SF268 cells after 72 hrs by celltiter-glo assay	[PMID: 20873740]
SF-268	IC₅₀	0.0103 μM Compound: Gemcitabine	Antiproliferative activity against p53 deficient human SF268 cells after 72 hrs Antiproliferative activity against p53 deficient human SF268 cells after 72 hrs	[PMID: 18469809]
SF-539	IC₅₀	0.0198 μM Compound: Gemcitabine	Antiproliferative activity against human SF539 cells expressing p53 gene after 72 hrs by proliferative assay Antiproliferative activity against human SF539 cells expressing p53 gene after 72 hrs by proliferative assay	[PMID: 18469809]
SF-539	IC₅₀	0.02 μM Compound: Gemcitabine	Antiproliferative activity against human SF539 cells expressing p53 after 72 hrs by celltiter-glo assay Antiproliferative activity against human SF539 cells expressing p53 after 72 hrs by celltiter-glo assay	[PMID: 20873740]
SGC-7901	IC₅₀	3.58 μM Compound: 7	Cytotoxicity against human SGC7901 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human SGC7901 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C5MD00158G
SK-MEL-2	IC₅₀	7.11 μM Compound: Gemcitabine	Cytotoxicity against human SK-MEL-2 cells after 3 days by MTT assay Cytotoxicity against human SK-MEL-2 cells after 3 days by MTT assay	[PMID: 21711054]
SK-N-AS	IC₅₀	1.1 μM Compound: Gemcitabine	Cytotoxicity against human SK-N-AS cells after 3 days by MTT assay Cytotoxicity against human SK-N-AS cells after 3 days by MTT assay	[PMID: 21711054]
SK-OV-3	IC₅₀	> 10 μM Compound: Gemcitabine	Cytotoxicity against human SKOV3 cells after 3 days by MTT assay Cytotoxicity against human SKOV3 cells after 3 days by MTT assay	[PMID: 21711054]
SMMC-7721	IC₅₀	1.4 μM Compound: Gemcitabine	Anticancer activity against human SMMC-7721 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Anticancer activity against human SMMC-7721 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 33444848]
SW1573	IC₅₀	16 nM Compound: dFdc	Growth inhibition of SW1573 cells by SRB assay Growth inhibition of SW1573 cells by SRB assay	[PMID: 17602464]
SW1573	IC₅₀	275 nM Compound: dFdc	Growth inhibition of SW1573 cells by SRB assay in presence of dipyridamole Growth inhibition of SW1573 cells by SRB assay in presence of dipyridamole	[PMID: 17602464]
SW1573	IC₅₀	8.3 μM Compound: gemicitabine	Cytotoxicity against SW1573 cells after 72 hrs by SRB assay Cytotoxicity against SW1573 cells after 72 hrs by SRB assay	[PMID: 17419604]
SW1990	IC₅₀	1.2 μM Compound: Gemcitabine	Cytotoxicity against human SW1990 cells after 72 hrs by MTT assay Cytotoxicity against human SW1990 cells after 72 hrs by MTT assay	[PMID: 19362474]
SW1990	IC₅₀	2.3 μM Compound: Gemcitabine	Cytotoxicity against human SW1990 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SW1990 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27966950]
SW1990	IC₅₀	25.4 μM Compound: Gemcitabine	Cytotoxicity against human SW1990 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay Cytotoxicity against human SW1990 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay	[PMID: 34342431]
SW1990	IC₅₀	40.19 μM Compound: Gemcitabine	Anticancer activity against human SW1990 cells assessed as cell growth inhibition measured after 72 hrs by Cell-Titre Glo luminescent cell viability assay Anticancer activity against human SW1990 cells assessed as cell growth inhibition measured after 72 hrs by Cell-Titre Glo luminescent cell viability assay	[PMID: 34838335]
SW480	IC₅₀	0.0136 μM Compound: Gemcitabine	Antiproliferative activity against p53 deficient human SW480 cells after 72 hrs by proliferative assay Antiproliferative activity against p53 deficient human SW480 cells after 72 hrs by proliferative assay	[PMID: 18469809]
SW480	IC₅₀	1.7 μM Compound: Gemcitabine	Antiproliferative activity against human p53 deficient SW480 cells after 72 hrs by celltiter-glo assay Antiproliferative activity against human p53 deficient SW480 cells after 72 hrs by celltiter-glo assay	[PMID: 20873740]
SW-620	IC₅₀	5.62 μM Compound: 7	Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	10.1039/C5MD00158G
T-24	IC₅₀	< 0.0039 μM Compound: 1, gemcitabine, GEM, dFdC	Cytotoxicity against human T24 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid Cytotoxicity against human T24 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid	[PMID: 25874330]
T-24	IC₅₀	< 0.0039 μM Compound: 1, gemcitabine, GEM, dFdC	Cytotoxicity against human T24 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid Cytotoxicity against human T24 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid	[PMID: 25874330]
T-24	IC₅₀	0.0069 μM Compound: 1, gemcitabine, GEM, dFdC	Cytotoxicity against human T24 cells after 48 hrs by SRB assay Cytotoxicity against human T24 cells after 48 hrs by SRB assay	[PMID: 25874330]
T-24	IC₅₀	0.017 μM Compound: 1, gemcitabine, GEM, dFdC	Cytotoxicity against human T24 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid Cytotoxicity against human T24 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid	[PMID: 25874330]
T-24	IC₅₀	0.018 μM Compound: 1, gemcitabine, GEM, dFdC	Cytotoxicity against human T24 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid Cytotoxicity against human T24 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid	[PMID: 25874330]
T-24	IC₅₀	10.15 μM Compound: Gem	Antiproliferative activity against human T24 cells measured after 48 hrs by MTT assay Antiproliferative activity against human T24 cells measured after 48 hrs by MTT assay	[PMID: 35434624]
T-24	IC₅₀	10.15 μM Compound: Cpd G	Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 32827851]
TRAMP-C1A	IC₅₀	0.0037 μM Compound: Gemcitabine	Cytotoxicity against mouse TRAMP-C1A cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against mouse TRAMP-C1A cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 27010926]
TRAMP-C2H	IC₅₀	0.0037 μM Compound: Gemcitabine	Cytotoxicity against mouse TRAMP-C2H cells assessed as inhibition of cell growth measured after 72 hs by MTT assay Cytotoxicity against mouse TRAMP-C2H cells assessed as inhibition of cell growth measured after 72 hs by MTT assay	[PMID: 27010926]
U-266	IC₅₀	0.22 μM Compound: Gemcitabine	Antiproliferative activity against human U266 cells after 48 hrs by MTT assay Antiproliferative activity against human U266 cells after 48 hrs by MTT assay	[PMID: 27670098]
U2OS	IC₅₀	0.0907 μM Compound: Gemcitabine	Antiproliferative activity against human U2OS cells expressing p53 gene after 72 hrs by proliferative assay Antiproliferative activity against human U2OS cells expressing p53 gene after 72 hrs by proliferative assay	[PMID: 18469809]
U2OS	IC₅₀	0.18 μM Compound: Gemcitabine	Antiproliferative activity against human U2OS cells expressing p53 after 72 hrs by celltiter-glo assay Antiproliferative activity against human U2OS cells expressing p53 after 72 hrs by celltiter-glo assay	[PMID: 20873740]
U2OS	IC₅₀	0.18 μM Compound: Gemcitabine	Antiproliferative activity against human U2OS cells after 3 days by MTS assay Antiproliferative activity against human U2OS cells after 3 days by MTS assay	[PMID: 30281308]
U2OS	IC₅₀	0.18 μM Compound: Gemcitabine	Cytostatic activity against human U2OS cells after 3 days by MTS assay Cytostatic activity against human U2OS cells after 3 days by MTS assay	[PMID: 30108897]
U2OS	IC₅₀	0.18 μM Compound: Gemcitabine	Cytotoxicity against human U2OS cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against human U2OS cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 28221790]
U373-MAGI	EC₅₀	27.5 nM Compound: dFdC, Gem, Gemcitabine	Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry	[PMID: 24120088]
U373-MAGI	CC₅₀	284 μM Compound: Gemcitabine	Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 2.5 nM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM) Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 2.5 nM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM)	[PMID: 27117260]
U373-MAGI	EC₅₀	53.5 μM Compound: Gemcitabine	Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 2.5 nM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection meas Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 2.5 nM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection meas	[PMID: 27117260]
U373-MAGI	CC₅₀	62 μM Compound: dFdC, Gem, Gemcitabine	Cytotoxicity against human U373-MAGI cells by CellTitre-Glo assay Cytotoxicity against human U373-MAGI cells by CellTitre-Glo assay	[PMID: 24120088]
U-87MG ATCC	EC₅₀	> 100 μM Compound: 11	Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
U-87MG ATCC	IC₅₀	1.49 μM Compound: Gemcitabine	Cytotoxicity against human U87MG cells after 3 days by MTT assay Cytotoxicity against human U87MG cells after 3 days by MTT assay	[PMID: 21711054]
U-87MG ATCC	IC₅₀	5.21 μM Compound: 1; dFdC	Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
U-87MG ATCC	IC₅₀	8.2 nM Compound: gem; dFdC	Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue assay Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue assay	[PMID: 31469566]
U-937	IC₅₀	0.07 μM Compound: Gemcitabine	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 27670098]
Vero	CC₅₀	0.0043 μM Compound: Gemcitabine	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter analysis Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter analysis	[PMID: 33479570]
WM 266-4	IC₅₀	17.8 μM Compound: GEM	Inhibition of cell growth in human WM266-4 cells measured after 24 hrs Inhibition of cell growth in human WM266-4 cells measured after 24 hrs	[PMID: 34967607]

体外研究
(In Vitro)

Gemcitabine (购自 MedChem Express，0.003-1 μM；3 天) 有效且有效地杀死小鼠和人类衰老细胞^[4]。
Gemcitabine 抑制 BxPC-3、Mia Paca-2、PANC-1、PL-45 和 AsPC-1 细胞的生长，IC₅₀ 分别为 37.6、42.9、92.7、89.3 和 131.4 nM^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:	Non-senescent and replication-induced senescent new born dermal fibroblasts (NBFs)
Concentration:	0.003, 0.01, 0.03, 0.1, 0.3, 1 μM
Incubation Time:	3 days
Result:	Killed replication-induced senescent NBFs for 3 days with 11.0% cell viability.

体内研究
(In Vivo)

Gemcitabine 可通过气管内喷雾给大鼠给药，无明显毒性，最大耐受剂量为 4 mg/kg，每周一次，持续 9 周。在 2、4 和 6 mg/kg 剂量下，Gemcitabine 通过肺部给药的毒性低于口服给药^[2]。
在 LSL-Kras^G12D/+; LSL-Trp53^R172H; Pdx-1-Cre 处理过的小鼠，与安慰剂组相比，使用 Gemcitabine (50 mg/kg，ip) 或 DMAPT/Gemcitabine 组合的中位生存时间显著增加超过 30 天 (分别为 254.5 或 255 天与 217.5 天))^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

263.20

Formula

C₉H₁₁F₂N₃O₄

CAS 号

95058-81-4

性状

固体

颜色

White to off-white

中文名称

吉西他滨；双氟脱氧胞苷

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 200 mg/mL (759.88 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

Ethanol 中的溶解度 : 12.5 mg/mL (47.49 mM; 超声助溶)

H₂O 中的溶解度 : 6.25 mg/mL (23.75 mM; 超声助溶 (<60°C))

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.7994 mL	18.9970 mL	37.9939 mL
5 mM	0.7599 mL	3.7994 mL	7.5988 mL
10 mM	0.3799 mL	1.8997 mL	3.7994 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (19.00 mM); 澄清溶液

此方案可获得 ≥ 5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (19.00 mM); 澄清溶液

此方案可获得 ≥ 5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.62 mg/mL (9.95 mM); 澄清溶液
方案四

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.62 mg/mL (9.95 mM); 澄清溶液
方案五

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (7.90 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
方案六

请依序添加每种溶剂： 1% DMSO 99% Saline
Solubility: ≥ 0.52 mg/mL (1.98 mM); 澄清溶液

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： PBS
Solubility: 25 mg/mL (94.98 mM); 澄清溶液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.96%

选择批次：

Data Sheet (647 KB) SDS (393 KB)

COA (291 KB) HNMR (274 KB) RP-HPLC (206 KB) MS (70 KB) 元素分析报告 (215 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Wang H, et al. Enhanced efficacy of Gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrativenucleoside transporter 1. Anticancer Res. 2011 Oct;31(10):3171-80. [Content Brief]

[2]. Gagnadoux F, et al. Safety of pulmonary administration of gemcitabine in rats. J Aerosol Med. 2005 Summer;18(2):198-206 [Content Brief]

[3]. Yip-Schneider MT, et al. Dimethylaminoparthenolide and Gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013 Apr 17;13:194. [Content Brief]

[4]. Yusheng Cai, et al. Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res. 2020 Jul;30(7):574-589. [Content Brief]

Gemcitabine 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

H₂O / Ethanol / DMSO	1 mM	3.7994 mL	18.9970 mL	37.9939 mL	94.9848 mL
	5 mM	0.7599 mL	3.7994 mL	7.5988 mL	18.9970 mL
	10 mM	0.3799 mL	1.8997 mL	3.7994 mL	9.4985 mL
	15 mM	0.2533 mL	1.2665 mL	2.5329 mL	6.3323 mL
	20 mM	0.1900 mL	0.9498 mL	1.8997 mL	4.7492 mL
Ethanol / DMSO	25 mM	0.1520 mL	0.7599 mL	1.5198 mL	3.7994 mL
	30 mM	0.1266 mL	0.6332 mL	1.2665 mL	3.1662 mL
	40 mM	0.0950 mL	0.4749 mL	0.9498 mL	2.3746 mL
DMSO	50 mM	0.0760 mL	0.3799 mL	0.7599 mL	1.8997 mL
	60 mM	0.0633 mL	0.3166 mL	0.6332 mL	1.5831 mL
	80 mM	0.0475 mL	0.2375 mL	0.4749 mL	1.1873 mL
	100 mM	0.0380 mL	0.1900 mL	0.3799 mL	0.9498 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Gemcitabine95058-81-4LY 188011吉西他滨双氟脱氧胞苷LY188011LY-188011Nucleoside Antimetabolite/AnalogDNA/RNA SynthesisAutophagyApoptosisInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Gemcitabine (Synonyms: 吉西他滨; LY 188011)

Customer Review

Other Forms of Gemcitabine:

MCE 顾客使用本产品发表的 151 篇科研文献

Gemcitabine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Gemcitabine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Gemcitabine (Synonyms: 吉西他滨; LY 188011)

Customer Review

Other Forms of Gemcitabine:

Gemcitabine 相关抗体

MCE 顾客使用本产品发表的 151 篇科研文献

Gemcitabine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

Gemcitabine 相关抗体:

摩尔计算器

稀释计算器

Gemcitabine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z